NAT2*5/*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians

Therapeutic Drug Monitoring

Volumn 27, Issue 3, 2005, Pages 297-304

  El Desoky, Ehab S ^a,b   AbdelSalam, Yasser M ^b   Salama, Ragaa H ^a   El Akkad, Magdy A ^b   Atanasova, Srebrena ^c   Von Ahsen, Nicolas ^c   Armstrong, Victor W ^c   Oellerich, Michael ^c  

^a ASSIUT UNIVERSITY   (Egypt)

^b Assiut University Faculty of Medicine   (Egypt)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Arylamine N acetyl transferase; Bilharzia; Genotype; NAT2; Schistosomiasis; Urinary bladder cancer

Indexed keywords

ALLOENZYME; AMINE; ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE N ACETYLTRANSFERASE 2; CARCINOGEN; UNCLASSIFIED DRUG; NAT2 PROTEIN, HUMAN;

ACETYLATOR PHENOTYPE; ADULT; ANIMAL TISSUE; ARAB; ARTICLE; BLADDER CANCER; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACETYLATION; EGYPT; ENZYME MECHANISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTOXICITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MUTANT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SCHISTOSOMIASIS; URINARY TRACT INFECTION; ACETYLATION; AGED; BLADDER TUMOR; FEMALE; GENETICS; GENOTYPE; MALE; MIDDLE AGED; MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ACETYLATION; ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SCHISTOSOMIASIS; URINARY BLADDER NEOPLASMS;

EID: 20044391429     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000164197.95494.aa     Document Type: Article

References (62)

1. Peter M, Dorit A, Eberhard S, et al. Prediction of metabolic activity from genotype: The gene-dose effect of N-acetyltransferase. Ther Drug Monit. 2001;23:9-14.
2. Hughes HB, Biehl JP, Jones AP, et al. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Respir Dis. 1954;70:266-273.
3. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazide metabolism in man. BMJ. 1960;ii:485-491.
4. Evans DAP. N-Acetyltransferase. PharmacolTher. 1989;42:157-234.
5. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphism. Cancer Epidemiol Biomarkers Prev. 2000;9:29-42.
6. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta. 1988;948:37-66.
7. Ogolla F, Ferguson RJ, Kirlin WG, et al. Acetylator genotype-dependent expression of arylamine N-acetyltransferase and N-hydroxy-arylamine O-acetyltransferase in Syrian inbred hamster intestine and colon: identity with the hepatic acetylation polymorphism. Drug Metab Dispos. 1990;18:680-685.
8. Turesky RJ, Lang NP, Butler MA, et al. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis. 1991;12:1839-1845.
9. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993;14:1633-1638.
10. Hein DW, Rustan TD, Ferguson RJ, et al. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol. 1994;68:129-133.
11. Minchin RF, Reeves PT, Teitel CH, et al. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun. 1992;185:839-844.
12. Filiadis IF, Georgiou I, Alamanos Y, et al. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J Urol. 1999;161:1672-1675.
13. Hung RJ, Boffetta P, Brennan P, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004;110:598-604.
14. Hao GY, Zhang WD, Chen YH, et al. Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer. Zhonghua Zhong Liu Za Zhi. 2004;26:283-286.
15. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics. 2000;10:115-122.
16. Hein DW, Doll MA, Rustan DT. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 1995;55:3531-3536.
17. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003;17:27-41.
18. Soliman AS, Bondy ML, Raouf AA, et al. Cancer mortality in Menofeia, Egypt: comparison with US mortality rates. Cancer Causes Control. 1999;10:349-354.
19. Abdel Mohsen MA, Hassan AAM, Eswedy SM, et al. Biomonitoring of N-nitroso compounds, nitrite and nitrate in the urine of Egyptian bladder cancer patients with or without Schistosoma haematobium infection. Int J Cancer. 1999;82:789-794.
20. Shaw ME, Elder PA, Abbas A, et al. Partial allelotype of schistosomiasis-associated bladder cancer. Int J Cancer. 1999;80:656-661.
21. Warren W, Biggs PJ, el-Baz M, et al. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis. 1995;16:1181-1189.
22. Badawi AF, Mostafa MH, Probert A, et al. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. Eur J Cancer Prev. 1995;4:45-59.
23. Ghazaly GE, Zakahary MM, el-Aziz MA, et al. Expression of glutathione S-transferase activity and glutathione content in squamous cell carcinoma of bladder associated with schistosomiasis in a population in Egypt. Scand J Urol Nephrol. 1997;31:43-47.
24. Aly MS, Khaled HM. Chromosomal aberrations in Bilharzial bladder cancer as detected by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1999;114:62-67.
25. Khaled HM, Aly MS, Magrath IT. Loss of Y chromosome in bilharzial bladder cancer. Cancer Genet Cytogenet. 2000;117:32-36.
26. Abdel-Salam IM, Khaled HM, Gaballah HE, et al. Telomerase activity in bilharzial bladder cancer. Prognostic implications. Urol Oncol. 2001;6:149-153.
27. Khaled HM, Bahnassi AA, Zekri AR, et al. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol. 2003;21:334-341.
28. Gutirrez MI, Siraj AK, Khaled H, et al. CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Mod Pathol. 2004;17:1268-1274.
29. Hicks RM, Walters CL, Elsebai I, et al. Demonstration of nitrosamines in human urine: preliminary observations on a possible etiology for bladder cancer in association with chronic urinary tract infections. Proc R Soc Med. 1977;70:413-417.
30. Ohshima H, Calmels S, Pignatelli B, et al. N-Nitrosamine formation in urinary-tract infections. IARC Sci Publ. 1987;84:384-390.
31. Tricker AR, Mostafa MH, Spiegelhalder B, et al. Urinary excretion of nitrate, nitrite and N-nitroso compounds in schistosomiasis and bilharzia bladder cancer patients. Carcinogenesis. 1989;10:547-552.
32. Hamdy SI, Hiratsuka M, Narahara K, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55:560-569.
33. Vesell E, Gaylor D. Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods. Pharmacogenetics. 1995;5:18-23.
34. Cartwright RA, Glashan RW, Rogers HJ, et al. A role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982;2:842-845.
35. Cascorbi I, Drakoulis N, Brockmoller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995;57:581-592.
36. Cascorbi I, Roots I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics. 1999;9:123-127.
37. ElAzab AS. Study of patterns of bladder cancer in Upper Egypt. Thesis submitted for Master Degree in Urology, Faculty of Medicine, Assiut University, Assiut, Egypt, 1997.
38. Atanasova S, von Ahsen N, Dimitrov TZ, et al. First study of NAT1 and NAT2 polymorphisms in Bulgarian patients with Balkan Endemic nephropathy (BEN) and healthy control. Biotechnol & Biotechnol Eq. 2004;18:95-103.
39. Bu R, Gutierrez MI, Al-Rasheed M, et al. Variable drug metabolism genes in Arab population. Pharmacogenomics J. 2004;4:260-266.
40. Watters AD, Stacey MW, Going JJ, et al. Genetic aberrations of NAT2 and chromosome 8: their association with progression in transitional cell carcinoma of the urinary bladder. Urol Int. 2001;67:235-239.
41. Woolhouse NM, Qureshi MM, Bastaki SM, et al. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics. 1997;7:73-82.
42. Ait Moussa L, Khassouani CE, Hue B, et al. Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe. Int J Clin Pharmacol Ther. 2002;40:548-553.
43. Lin HJ, Han CY, Lin BK, et al. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 1994;4:125-134.
44. Cascorbi I, Drakoulis N, Brockmoller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995;57:581-592.
45. Smith CAD, Wadelius M, Gough AC, et al. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet. 1997;34:758-760.
46. Bakayev W, Mohammadi F, Bahadori M, et al. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol. 2004;60:467-471.
47. Fretland AJ, Leff MA, Doll MA, et al. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics. 2001;11:207-215.
48. Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol. 2003;41:1226-1232.
49. Yildiz A, Sever M, Turkmen A, et al. Tuberculosis after renal transplantation: experience of one Turkish center. Nephrol Diol Transplant. 1998;13:1872-1875.
50. Elagroudy AE, Refaie AF, Moussa OM, et al. Tuberculosis in Egyptian kidney transplant recipients: study of clinical course and outcome. J Nephrol. 2003;16:404-411.
51. Rothman N, Hayes RB, Bi W, et al. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics. 1993;3:250-255.
52. Kantor AF, Hartge P, Hoover RN, et al. Urinary tract infection and risk of bladder carcinoma. Am J Epidemiol. 1984;119:510-515.
53. Bedwani REL, Khwsky F, Lavecchia S, et al. Descriptive epidemiology of bladder cancer in Egypt. Int J Cancer. 1993;55:351-352.
54. Koraitim MM, Metwalli NE, Atta MA, et al. Changing age incidence and pathological types of schistosoma-associated bladder cancer. J Urol. 1995;154:1714-1716.
55. Grant DM, Goodfellow GH, Sugamri KS, et al. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology. 2000;61:204-211.
56. Cavaco I, Reis R, Gil JP, et al. CYP3A4*1B and NAT2*14 alleles in a native African population. Clin Chem Lab Med. 2003;41:606-609.
57. Kontani K, Kawakami K, Nakajima T, et al. Tobacco use and occupational exposure to carcinogens, but not N-acetyltransferase 2 genotypes are major risk factors for bladder cancer in the Japanese. Urol Res. 2001;29:199-204.
58. Schnakenberg E, Lustig M, Breuer R, et al. Gender specific effects of NAT2 and GSTM1 in bladder cancer. Clin Genet. 2000;57:270-277.
59. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002;506-507:65-77.
60. Vineis P. The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology. 2002;181-182:457-462.
61. Habuchi T, Takahashi R, Yamada H, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res. 1993;53:3795-3799.
62. Khaled HM, Bahnassi AA, Zekri AR, et al. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol. 2003;21:334-341.